ClinVar Miner

Submissions for variant NM_030662.4(MAP2K2):c.420C>T (p.Asp140=)

gnomAD frequency: 0.00016  dbSNP: rs369925884
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen RASopathy Variant Curation Expert Panel RCV000521680 SCV000616582 benign RASopathy 2017-05-09 reviewed by expert panel curation The filtering allele frequency of the c.420C>T (p.Asp140=) variant in the MAP2K2 gene is 0.271% (32/8604) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)
PreventionGenetics, part of Exact Sciences RCV000039481 SCV000314687 benign not specified criteria provided, single submitter clinical testing
GeneDx RCV000039481 SCV000513521 benign not specified 2015-06-08 criteria provided, single submitter clinical testing This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000587230 SCV000699637 benign not provided 2016-11-14 criteria provided, single submitter clinical testing Variant summary: The MAP2K2 c.420C>T (p.Asp140Asp) variant involves the alteration of a non-conserved nucleotide, resulting in a synonymous change. 5/5 splice prediction tools predict no significant impact on normal splicing. This variant was found in 45/121454 control chromosomes (1 homozygote) at a frequency of 0.0003705, which is approximately 148 times the estimated maximal expected allele frequency of a pathogenic MAP2K2 variant (0.0000025), suggesting this variant is likely a benign polymorphism. The variant has been reported in patients/families with metachondromatosis, autism and carcinoma of large intestine, without strong evidence for pathogenicity (COSMIC, Bowen_2011, Kelleher_2012). In addition, multiple clinical diagnostic laboratories have classified this variant as benign. Taken together, this variant is classified as Benign.
Invitae RCV000521680 SCV000776924 benign RASopathy 2024-01-25 criteria provided, single submitter clinical testing
Genome Diagnostics Laboratory, The Hospital for Sick Children RCV001813365 SCV002060575 benign Noonan syndrome and Noonan-related syndrome 2021-01-15 criteria provided, single submitter clinical testing
Ambry Genetics RCV002326746 SCV002627335 likely benign Cardiovascular phenotype 2022-03-06 criteria provided, single submitter clinical testing This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000039481 SCV000063168 benign not specified 2009-06-26 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.